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DNA vaccines showed great promise in preclinical models of infectious and malignant diseases, but their potency was insuﬃcient
in clinical trials and is needed to be improved. In this study, we tested systemic administration of two conventional adjuvants,
synthetic oligodeoxynucleotide carrying immunostimulatory CpG motifs (CpG-ODN) and levamisole (LMS), and evaluated their
eﬀect on immune reactions induced by DNA vaccines delivered by a gene gun. DNA vaccination was directed either against the E7
oncoprotein of human papillomavirus type 16 or against the BCR-ABL1 oncoprotein characteristic for chronic myeloid leukemia.
High doses of both adjuvants reduced activation of mouse splenic CD8+ T lymphocytes, but the overall antitumor eﬀect was
enhanced in both tumor models. High-dose CpG-ODN exhibited a superior adjuvant eﬀect in comparison with any combination
ofCpG-ODNwithLMS.Insummary,ourresultsdemonstratethebeneﬁtofcombinedtherapywithgene-gun-deliveredantitumor
DNA vaccines and systemic administration of CpG-ODN or LMS.
1.Introduction
After pioneering studies showing the expression of protein
antigens from plasmid DNA and the ability of these antigens
to induce both humoral and cell-mediated immunity in the
early 1990s [1–3], DNA vaccines against some infectious dis-
eases and also malignant tumors were quickly developed and
successfully tested in animal models. However, the eﬃcacy of
DNAimmunizationininitialclinicaltrialswasdisappointing
[4].
Immune reactions induced by DNA vaccines can be en-
hanced by adjuvants that are classiﬁed into two groups by
Sasakietal.[5]—geneticandconventional.Whilegeneticad-
juvants are plasmids producing cytokines, chemokines or
other immunomodulatory molecules, conventional adju-
vants are chemicalcompounds increasing or modulating im-
mune responses. As genetic adjuvants are of the same nature
as DNA vaccines, they can be easily codelivered in any
method of DNA vaccine administration. However, conven-
tional adjuvants can be mixed and codelivered with DNA
vaccinesinjectedasasolution,buttheircodeliverywithDNA
vaccines administered via a gene gun is limited by the mode
of application. Only local application of the conventional
adjuvant imiquimod was more widely tested in combination
with gene-gun delivery of plasmid DNA [6, 7].
Of ﬁve conventional (chemical) adjuvants tested after
addition to an intramuscular DNA vaccine, levamisole
(LMS), a synthetic phenylimidazolthiazole, induced the
strongestTh1immunereactions[8].Thehighimmunostim-
ulatory activity of LMS in DNA vaccination was conﬁrmed
in subsequent studies [9, 10]. This compound developed as
an anthelmintic drug in the 1960s is also recommended, in
combination with 5-ﬂuorouracil, as adjuvant chemotherapy
for colon cancer [11, 12].
Moreover, the eﬀect of DNA vaccination is supported by
immunostimulatory unmethylated CpG motifs that can be2 Clinical and Developmental Immunology
either carried by an immunization plasmid itself or delivered
on synthetic oligodeoxynucleotides (ODNs) [13]. Demon-
strated in animal models, the beneﬁt of ODNs carrying
CpG motifs (CpG-ODN) after addition to various types of
vaccines was evaluated in clinical trials [14, 15]. However,
systemic administration of ODNs caused suppression of
splenic cytotoxic T lymphocytes (CTLs) in mice, which
raised concerns for the usability of CpG-ODN in antitumor
therapy.Thiseﬀectwasassociatedwithenhancedproduction
of indoleamine 2,3-dioxygenase (IDO) by splenic CD19+
dendritic cells (DCs) [16, 17]. Systemic injection of CpG-
ODN also diminished cross-presentation of antigens by
DCs [18]. On the other hand, repeated systemic admin-
istration of high doses of CpG-ODN induced immune-
mediated protection from acute lymphoblastic leukemia
[19].
In this study, we evaluated the inﬂuence of systemic
administration of LMS and CpG-ODN on the activa-
tion of mouse splenic CTLs by gene-gun DNA vaccina-
tion and on the antitumor eﬀe c te l i c i t e di nm o d e l so f
chronic myeloid leukemia (CML) and human-papillomavi-
rus- (HPV-) induced tumors. These adjuvants were com-
pared for potency and combined treatment was examined as
well.
2.MaterialsandMethods
2.1. Plasmids. The plasmids pBSC [20], pBSC/bcr-abl [21],
pBSC/E7GGG.GUS [22], and pBSC/EGGG.LAMP [23]w e r e
used for immunization. The plasmid pBSC/bcr-abl produces
the protein BCR-ABL1 (p210) from the fusion gene gener-
ated by the b3a2 chromosomal translocation t(9; 22) in a
CML patient. The fusion gene E7GGG.GUS consists of the
mutated HPV16 E7 gene (E7GGG) containing three point
mutations resulting in substitutions D21G, C24G, and E26G
in the Rb-binding site [20] and the gene encoding E. coli β-
glucuronidase (GUS). In the E7GGG.LAMP gene, E7GGG
was fused with two signal sequences of lysosome-associated
membrane protein 1 (LAMP-1).
2.2. Cell Lines. TC-1 cells, kindly provided by T. C. Wu
(Johns Hopkins University, Baltimore, Md), were prepared
by the transformation of C57BL/6 mouse primary lung cells
with the HPV16 E6/E7 oncogenes and the activated human
H-ras gene [24]. TC-1 cells were grown in high glucose
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM; PAA Labora-
tories,Linz,Austria)supplementedwith10%fetalcalfserum
(FCS; PAA), 2mM L-glutamine, 100U/mL penicillin, and
100μg/mL streptomycin.
12B1 cells producing the BCR-ABL1 (b3a2) protein
[25] were obtained through the courtesy of E. Katsanis
(University of Arizona, Tucson, Ariz). They were derived
by transformation of BALB/c mouse primary bone marrow
cells with a retrovirus-derived vector carrying the BCR-
ABL1 fusion gene. 12B1 cells were passaged in RPMI-1640
medium (Sigma-Aldrich, St. Louis, Mont) supplemented
with 10% FCS, 1mM pyruvate, 50mM 2-mercaptoethanol,
L-glutamine, and antibiotics.
2.3. Mice. Six- to eight-week-old female C57BL/6 (H-2b)
or BALB/c mice (H-2d; Charles River, Germany) were used
in immunization experiments. Animals were maintained
under standard conditions at the Center for Experimental
Biomodels, Charles University, Prague.
2.4. Immunization Experiments. Plasmid DNA was coated
onto 1μm gold particles (Bio-Rad, Hercules, Calif) as
described previously [20]. Mice were immunized with
plasmids by a gene gun (Bio-Rad) at a discharge pressure
of 400psi into the shaven skin of the abdomen. Each
immunization consisted of one or two shots delivering 1 or
2μg of plasmid DNA.
For in vitro examination of immune reactions, C57BL/6
mice (three per group) were immunized with two 1μg
doses of the E7GGG.GUS plasmid given one week apart. In
therapeutic immunization experiments, C57BL/6 or BALB/c
mice (six per group) were ﬁrst s.c. administered 3 × 104
TC-1 or 5 × 103 12B1 cells suspended in 150μL or 200μL
PBS, respectively, into the back and then vaccinated with
pBSC/E7GGG.LAMP (1μg doses three and ten days after
cell inoculation) or pBSC/bcr-abl (2μg doses three, six,
and ten days after cell inoculation), respectively. The empty
pBSC plasmid was used as a negative control. Tumor cells
were administered under anesthesia with intraperitoneal
etomidate (0.5mg/mouse; Janssen Pharmaceutica, Beerse,
Belgium). Tumor growth was monitored twice a week,
and tumor size was calculated from three perpendicular
measurements using the formula (π/6) (a × b × c). Mice
were sacriﬁced when tumor volume reached 1cm3 or two
months after cell inoculation.
The adjuvants phosphorothioate-stabilized oligodeox-
ynucleotide ODN1826 carrying CpG immunostimulatory
motifs (TCCATGACGTTCCTGACGTT; Generi Biotech,
Hradec Kralove, Czech Republic) and LMS (Sigma-Aldrich)
dissolvedin200μLPBSwerei.p.injectedonthedaysofDNA
vaccination.
2.5. Tetramer Staining. A week after immunization with
pBSC/E7GGG.GUS, tetramer staining was performed as
described previously [26]. In brief, lymphocyte bulk cul-
tures were prepared from splenocytes of three immunized
animals and restimulated with the HPV16 E749−57 peptide
(RAHYNIVTF) for 6 days. After incubation with anti-
mouse CD16/CD32 antibody (Fc-block; BD Biosciences, San
Diego, Calif), lymphocytes were stained with a mixture
of H-2Db/E749−57-PE tetramers (Sanquin, Amsterdam, The
Netherlands) and anti-mouse CD8a-FITC antibody (BD
Biosciences). The stained cells were measured on a Coulter
Epics XL ﬂow cytometer (Coulter, Miami, Fla) and analyzed
by FlowJo 7.2.2 software (TreeStar, Ashland, Ore).
2.6.StatisticalAnalysis. Tumorgrowthwasevaluatedbytwo-
way analysis of variance, tumor formation by log-rank test,
and the expansion of E7-speciﬁc splenocytes in tetramer
a s s a yb yS t u d e n t ’ st test. Results were considered signiﬁcantly
diﬀerent if P<0.05. Calculations were performed usingClinical and Developmental Immunology 3
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Figure 1: Antitumor eﬀect of systemic administration of high-dose adjuvants. C57BL/6 or BALB/c mice (n = 6) were s.c. inoculated with 3
× 104 TC-1 (a, b) or 5 × 103 12B1 cells (c, d) and immunized by a gene gun with 1μg of pBSC/E7GGG.LAMP three and ten days later or
with 2μg of pBSC/bcr-abl three, six, and ten days later, respectively. The pBSC plasmid was used as a negative control. CpG-ODN (50μg; a,
c) or LMS (200μg; b, d) was i.p. injected on the days of DNA vaccination. No. of mice with a tumor/no. of mice in the group is indicated.
Bars: ±SD; ∗P<0.05; ∗∗P<0.01.4 Clinical and Developmental Immunology
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Figure 2: Detection of E7-speciﬁc splenic CTLs after DNA vaccination combined with systemic administration of adjuvants. C57BL/6 mice
(n = 3) were twice immunized at a 1-week interval with 1μg of pBSC or pBSC/E7GGG. GUS by a gene gun and i.p. injected with indicated
doses of CpG-ODN (a) or LMS (b). One week after the second immunization, lymphocyte bulk cultures were prepared from splenocytes,
restimulated with the RAHYNIVTF peptide for 6 days, and stained with a mixture of H-2Db/E749−57-PE tetramers and anti-mouse CD8a-
FITC antibody. Control lymphocytes were cultured without the peptide. Columns: mean of duplicate samples; bars: ±SD; ∗P<0.05 (the
comparison with the E7GGG.GUS group).
GraphPad Prism 5.0 software (GraphPad Software, San
Diego, Calif).
3. Results
3.1. Systemic Administration of High-Dose CpG-ODN or LMS
Supports Antitumor Eﬀect of Gene-Gun DNA Vaccination.
We tested the inﬂuence of systemic application of CpG
or LMS on antitumor eﬀect induced by DNA vaccines
delivered with a gene gun in two mouse tumor models: TC-1
cells producing the HPV16 E7 oncoprotein and 12B1 cells
producing the BCR-ABL1 fusion protein injected s.c. into
C57BL/6 and BALB/c mice, respectively. Because of high
eﬃcacy of immunization against the E7 antigen, we used the
pBSC/E7GGG.LAMP plasmid that is less immunogenic than
pBSC/E7GGG.GUS and applied only two 1μgd o s e s .T h e
plasmid pBSC/bcr-abl is potent in preventive immunization
against 12B1 cells [27], but its eﬃcacy in therapeutic
immunization is low. Therefore, vaccination against 12B1
cells consisted of three 2μgd o s e s .
For initial experiments, we chose relatively high doses
of adjuvants: 50μg of CpG-ODN and 200μgo fL M S .B o t h
adjuvants reduced the growth of TC-1-induced tumors in
animals either immunized or nonimmunized against the E7
antigen, but this eﬀect was nonsigniﬁcant (Figures 1(a) and
1(b)). However, while adjuvants alone did not aﬀect 12B1-
induced tumors, they signiﬁcantly reduced tumor growth
after combination with vaccination (CpG-ODN: P = 0.027,
LMS: P = 0.008; Figures 1(c) and 1(d)). Moreover, in both
tumor models, administration of adjuvants to immunized
mice resulted in inhibition of tumor formation in a portion
of animals. This eﬀect was signiﬁcant for combination of
pBSC/bcr-abl immunization and LMS administration (P =
0.019).
3.2. Systemic Administration of High Doses of CpG-ODN
or LMS Reduces the Stimulation of Splenic CTLs by Gene-
Gun DNA Vaccination. As systemic inoculation of 50μgo f
CpG-ODN has been reported to reduce the CTL activity
induced by immunization [16, 17], we evaluated this eﬀectClinical and Developmental Immunology 5
6/6
6/6
1000
800
600
400
200
0
M
e
a
n
t
u
m
o
r
s
i
z
e
(
m
m
3
)
Days after TC-1 inoculation
∗
0 10 20 30 40
2/6
2/6
4/6
pBSC
E7GGG. LAMP
E7GGG. LAMP + CpG 50
E7GGG. LAMP + CpG 5
E7GGG. LAMP + CpG 0.5
(a)
3/6
5/6
1000
800
600
400
200
0
M
e
a
n
t
u
m
o
r
s
i
z
e
(
m
m
3
)
Days after TC-1 inoculation
0 10 20 30 40
6/6
6/6
6/6
pBSC
E7GGG. LAMP
E7GGG. LAMP + LMS 2
E7GGG. LAMP + LMS 20
E7GGG. LAMP + LMS 200
(b)
1000
800
600
400
200
0
M
e
a
n
t
u
m
o
r
s
i
z
e
(
m
m
3
)
Days after TC-1 inoculation
01 0 20 30 40
3/6
3/6
5/6
6/6
6/6
pBSC
E7GGG. LAMP
E7GGG. LAMP + CpG 50 + LMS 200
E7GGG. LAMP + CpG 5 + LMS 20
E7GGG. LAMP + CpG 0.5 + LMS 2
(c)
Figure 3: Antitumor eﬀect of systemic administration of single adjuvants or their combinations. C57BL/6 mice (n = 6) were s.c. inoculated
with 3 × 104 TC-1 cells and immunized by a gene gun with 1μg of pBSC/E7GGG.LAMP three and ten days later. The pBSC plasmid was
used as a negative control. CpG-ODN (a), LMS (b), or their combinations (c) were i.p. injected at indicated doses on the days of DNA
vaccination. The graphs (a), (b), and (c) were constructed from the results of the same experiment. No. of mice with a tumor/no. of mice in
the group is indicated. Bars: ±SD; ∗P<0.05.6 Clinical and Developmental Immunology
for CpG-ODN and LMS after vaccination of C57BL/6
mice with the pBSC/E7GGG.GUS plasmid. The stimulation
of splenic CTLs speciﬁc for the H-2Db E7 epitope was
measured after the addition of CpG-ODN or LMS at doses
used for enhancement of the antitumor eﬀect of the DNA
vaccines (i.e., 50μg and 200μg, resp.) and two lower doses
(5 and 0.5μg for CpG-ODN and 20 and 2μgf o rL M S ) .
Both adjuvants exhibited reduction of E7-speciﬁc CD8+ T
lymphocytes in the spleens (Figure 2). The extent of this
inhibitionwassimilarforthehighest(P<0.05)andmedium
doses of CpG-ODN and LMS, but, while the lowest dose of
LMS was still inhibiting CTL response (Figure 2(b)), that of
CpG-ODN moderately increased it (Figure 2(a)).
3.3. Combination of CpG-ODN and LMS Does Not Out-
perform CpG-ODN Alone in Supporting Antitumor Eﬀect of
Gene-Gun DNA Vaccination. Showing lower inhibition of
CTLs with lower doses of adjuvants, we next compared the
antitumor eﬀects of the three doses in the model of TC-
1-induced tumors. Simultaneously, we tested combinations
of both adjuvants. In control mice immunized with the
pBSC/E7GGG.LAMP plasmid, tumor growth was markedly
reduced in comparison with pBSC-treated mice, but tumors
developed in all animals (Figure 3). For CpG-ODN, the
highest dose of the adjuvant (50μg) most eﬃciently sup-
ported antitumor immunity elicited by DNA vaccination—
tumor formation was inhibited in four out of six mice
(P = 0.005) and tumor growth was signiﬁcantly reduced
(P = 0.033; Figure 3(a)). Conversely, the administration of
the lowest dose of LMS (2μg) resulted in the lowest tumor
rate (3/6, P = 0.034; Figure 3(b)). Combinations of high
and medium doses of adjuvants provided the best antitumor
eﬀects (tumor rate 3/6, P = 0.020 and P = 0.041, resp.;
Figure 3(c)), but none of them outperformed the high-dose
CpG-ODN in terms of potency.
4. Discussion
Successful examination of DNA vaccines in animals resulted
in license acquisition by several veterinary vaccines directed
against both infectious and malignant diseases. The evalu-
ation of DNA vaccines in clinical trials showed that these
vaccines were well tolerated and safe, but their immuno-
genicity was unexpectedly lower than in preclinical models.
In recent years, progress in enhancing the eﬃcacy of DNA
vaccination in humans has been achieved mainly thanks to
the improvement of physical delivery methods, with muscle
electroporation and particle bombardment of the skin being
currently predominant [28].
Utilization of adjuvants that is crucial for a high eﬃcacy
of protein and peptide vaccines is still in its infancy
in DNA immunization. Their introduction into clinical
immunization with DNA vaccines could be another step
in the enhancement of DNA vaccination eﬃcacy. In this
study, we tested systemic administration of two adjuvants,
CpG-ODN and LMS, in combination with gene-gun DNA
immunization and evaluated adjuvant-mediated impact on
the antitumor eﬀect induced by DNA vaccines.
At high doses, both adjuvants reduced activation of spe-
ciﬁc splenic CTLs, but, overall, they enhanced the antitumor
potency of DNA vaccination. Inhibition of splenic CTLs
by CpG-ODN has already been reported, and increased
expression of IDO by splenic CD19+ DCs has been identiﬁed
as a key factor in this process [16, 17]. However, CpG-ODN
directly or indirectly aﬀects other immune cells, including
diﬀerent types of DCs, T cells, NK cells, B cells, monocytes,
and neutrophils, that can contribute to reduced tumor
growth [29]. Similarly, LMS activates DCs and induces
their maturation, which leads to stimulation of CTLs [30].
Thus, complex activation of the immune system by the two
systemically delivered adjuvants can result in strengthened
immunity in the tumor despite mild immunosuppression in
the spleen.
CpG-ODN and LMS activate DCs by binding to Toll-
like receptor- (TLR-) 9 and TLR-2 [30], respectively. Both
adjuvants induce production of IL-12 and stimulate Th1
immune response. Our comparison showed higher potency
of CpG-ODN in enhancement of antitumor eﬀect against
mouse TC-1 tumor cells. Combinations of various doses of
CpG-ODN and LMS did not further increase the impact
on tumor growth. However, subsets of mouse and human
DCs diﬀer in TLR-9 and TLR-2 expression [31]: while all
mouse DC subsets produce both TLRs, human myeloid DCs
produce only TLR-2 and plasmacytoid DCs only TLR-9.
Then, in humans, the combination of CpG-ODN and LMS
can be useful in antitumor treatment.
Systemic administration of CpG-ODN is well toler-
ated and induces Th1 immune response in humans [32].
As preclinical models demonstrated improved eﬀect of
chemotherapy after addition of CpG-ODN, clinical trials
examining this combined treatment have also been launched
[14]. Furthermore, recent results in mouse tumor models
suggested the potential of systemic administration of CpG-
ODN in the inhibition of metastasis [33] and treatment
of minimal residual disease [19]. This study showed that
vaccination could supplement such methods of antitumor
therapy with systemic CpG-ODN delivery.
5. Conclusions
Our results demonstrate that in spite of partial inhibition
of speciﬁc immunity by systemic administration of high-
dose CpG-ODN or LMS, these adjuvants potentiated the
antitumor eﬀect of DNA vaccines delivered by a gene gun.
CpG-ODN was more eﬃcient than LMS, and combination
of both adjuvants did not outperform CpG-ODN alone in
termsofpotency.Toconclude,weproposeanewapproachto
enhancing antitumor gene-gun DNA vaccination: systemic
CpG-ODN delivery.
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